Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, is hosting an in-person investor day today in New York City to discuss the Company’s current vaccine pipeline, commercial products, and future directions. Valneva’s Chief Executive Officer Thomas Lingelbach, Chief Financial Officer Peter Bühler, and other members of the Company’s senior leadership team will highlight Valneva’s core near- and mid-term value drivers, including its early- and late-stage development pipeline and commercial vaccine business.
Presentations will begin at 10am Eastern Time. The event will also be webcast live and archived on the Events and Presentations page in the Investors section of Valneva’s website. A live Q&A session will follow the formal presentations with opportunity for virtual attendees to participate. To register for the event, please click here.
Valneva will highlight its late-stage clinical and select preclinical vaccine candidates:
- VLA15, a Lyme Borreliosis (Lyme disease) vaccine candidate that is partnered with Pfizer for global development and commercialization, currently enrolling a pivotal Phase 3 study
- VLA1553, a chikungunya virus vaccine candidate for which rolling submission of a Biologics License Application (BLA) is nearing completion
- VLA1554, a proprietary recombinant protein subunit candidate comprised of stabilized pre-fusion F peptide as a potential prophylactic vaccine against the respiratory pathogen human metapneumovirus (hMPV)
- VLA2112, a recombinant protein subunit candidate comprised of a mix of relevant antigens as a potential second-generation prophylactic vaccine against Epstein-Barr virus (EBV)
Valneva will also provide a detailed overview of its current commercial products and the factors driving continued recovery and potential growth of this part of the business as the COVID-19 pandemic slows, followed by a brief financial overview.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.